Form 4: Quince Therapeutics Director Elects Stock Options Over Cash for 2025 Compensation

Rajiv Patni, a Director at Quince Therapeutics, Inc. (QNCX), has opted to receive 27,000 stock options in lieu of his annual cash retainer for 2025, aligning his compensation with shareholder interests.

Summary

• Rajiv Patni, a Director of Quince Therapeutics, Inc. (QNCX), was granted 27,000 Director Stock Options on June 4, 2025.
• These options have an exercise price of $1.09 per share.
• The options will vest 100% on the one-year anniversary of the grant date, specifically on June 4, 2026.
• The expiration date for these options is June 4, 2035.
• Mr. Patni elected to receive these stock options instead of the annual director cash retainer for 2025, as per the issuer's Outside Director Compensation Policy.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A director choosing equity over cash for compensation indicates confidence in the company's future and aligns their interests with shareholders, which is generally viewed favorably by the market.

Positives

• The director's decision to receive stock options instead of cash aligns his financial interests more closely with those of the shareholders, as the value of his compensation will be tied to the company's stock performance.
• This move demonstrates confidence from a key insider in the future prospects of Quince Therapeutics, Inc.

Future Outlook

The granted stock options are set to vest 100% on June 4, 2026, indicating a future milestone for the director's equity compensation.

Management Comments

• The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy.

Industry Context

It is a common practice in the biotechnology and pharmaceutical industries for directors to receive a portion of their compensation in equity, such as stock options, to align their interests with long-term company performance and shareholder value. This practice is particularly prevalent in growth-oriented sectors where cash flow might be prioritized for R&D or operational expenses.

Comparison to Industry Standards

• The practice of compensating directors with stock options in lieu of cash is a standard corporate governance practice, especially in the biotech sector, which often seeks to conserve cash and incentivize long-term value creation.
• While the specific number of options (27,000) and exercise price ($1.09) are unique to Quince Therapeutics and its compensation policy, the underlying mechanism is comparable to director compensation structures seen at companies like Moderna (MRNA) or BioNTech (BNTX), where equity-based incentives are a significant component of executive and director pay.

Corporate Governance

Stakeholder Impact

• Shareholders: The decision by a director to take equity compensation aligns his interests with shareholders, potentially signaling confidence in the company's future performance and long-term value creation.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel through equity.

Next Steps

• The 27,000 Director Stock Options granted to Rajiv Patni are scheduled to vest 100% on June 4, 2026.

Key Dates

Keywords

Quince Therapeutics, QNCX, SEC Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Compensation, Rajiv Patni, Biotechnology, Pharmaceuticals